The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:
What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?
What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?
Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.
Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria
Moderate-to-severe disease requiring systemic or advanced therapy
Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care
Evaluated in participating dermatology centers in Costa Rica
Lack of sufficient clinical data for severity or treatment assessment
The study population includes pediatric and adult patients with moderate-to-severe atopic dermatitis treated in dermatology referral centers in Costa Rica who require systemic immunomodulatory or biologic therapy. These patients represent individuals with more severe or refractory disease seen in specialized care settings, often with significant disease burden, chronic course, and impact on quality of life. The registry captures real-world clinical practice across participating centers and reflects the national population receiving advanced atopic dermatitis therapies.
Cohort
Prospective
Abrocitinib
DrugThis registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
Upadacitinib
DrugThis registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
Baricitinib
DrugThis registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
Dupilumab
Biological/VaccineThis registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
Change in atopic dermatitis severity over time
Measured using validated clinical severity scales EASI (Eczema Area and Severity Index)
Change in atopic dermatitis severity over time
Measured using the validated clinical severity scale SCORAD (SCORing Atopic Dermatitis) from baseline through follow-up visits during routine care.
Treatment patterns in moderate-to-severe atopic dermatitis
Type and duration of systemic or advanced therapies prescribed in real-world practice during the observation period.
Patient-reported quality of life
Change in Dermatology Life Quality Index (DLQI) scores over time during treatment.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: